AR060104A1 - Modulacion de la formacion de huesos - Google Patents

Modulacion de la formacion de huesos

Info

Publication number
AR060104A1
AR060104A1 ARP070100684A ARP070100684A AR060104A1 AR 060104 A1 AR060104 A1 AR 060104A1 AR P070100684 A ARP070100684 A AR P070100684A AR P070100684 A ARP070100684 A AR P070100684A AR 060104 A1 AR060104 A1 AR 060104A1
Authority
AR
Argentina
Prior art keywords
ror2
bone
modulation
bone formulation
activity
Prior art date
Application number
ARP070100684A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR060104A1 publication Critical patent/AR060104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Modulacion de la actividad de Ror (p. ej., la actividad de la proteína Ror2) y/o 14-3-3b para producir un efecto sobre la formacion o resorcion osea. Composiciones y métodos para el rastreo, el diagnostico y el desarrollo de terapias para trastornos relacionados con los huesos tales como osteoporosis y fractura de huesos. Los anticuerpos y fragmentos de anticuerpos dirigidos a la proteína Ror2 son particularmente utiles para producir dimerizacion de las proteínas Ror2, generando con ello la activacion de Ror2.
ARP070100684A 2006-02-17 2007-02-16 Modulacion de la formacion de huesos AR060104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13

Publications (1)

Publication Number Publication Date
AR060104A1 true AR060104A1 (es) 2008-05-28

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100684A AR060104A1 (es) 2006-02-17 2007-02-16 Modulacion de la formacion de huesos

Country Status (19)

Country Link
US (1) US20090047287A1 (es)
EP (1) EP1984395A2 (es)
JP (1) JP2009527485A (es)
KR (1) KR20080095269A (es)
AR (1) AR060104A1 (es)
AU (1) AU2007217779A1 (es)
BR (1) BRPI0707864A2 (es)
CA (1) CA2638803A1 (es)
CR (1) CR10212A (es)
EC (1) ECSP088682A (es)
IL (1) IL193271A0 (es)
MX (1) MX2008010511A (es)
NO (1) NO20083497L (es)
PA (1) PA8715601A1 (es)
PE (1) PE20071309A1 (es)
RU (1) RU2008131052A (es)
SV (1) SV2009002997A (es)
TW (1) TW200800266A (es)
WO (1) WO2007098198A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079246A1 (en) * 2010-05-05 2013-03-28 Addex Pharma Sa Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
EP2800975A4 (en) * 2012-01-03 2015-12-09 Univ Leland Stanford Junior ANALYSIS AND TARGETING OF ROR2 IN CANCER
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び／または品質評価を行う方法
SG11201610795VA (en) * 2014-08-01 2017-02-27 Purec Co Ltd Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
WO2017022628A1 (ja) * 2015-07-31 2017-02-09 国立大学法人大阪大学 上皮疾患に対する治療及び／又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
AU2017263568B2 (en) * 2016-05-13 2024-01-18 Bioatla, Llc Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
AU2001238571A1 (en) * 2000-03-14 2001-09-24 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
EP1603586A1 (en) * 2003-02-19 2005-12-14 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
JP2006524508A (ja) * 2003-04-16 2006-11-02 ワイス 骨関連の活性を調節する新規な方法

Also Published As

Publication number Publication date
CR10212A (es) 2008-10-03
KR20080095269A (ko) 2008-10-28
RU2008131052A (ru) 2010-03-27
ECSP088682A (es) 2008-09-29
PA8715601A1 (es) 2008-11-19
TW200800266A (en) 2008-01-01
PE20071309A1 (es) 2008-02-13
BRPI0707864A2 (pt) 2011-05-10
WO2007098198A3 (en) 2008-03-13
MX2008010511A (es) 2008-11-18
NO20083497L (no) 2008-10-31
WO2007098198A2 (en) 2007-08-30
IL193271A0 (en) 2011-08-01
JP2009527485A (ja) 2009-07-30
SV2009002997A (es) 2009-04-17
US20090047287A1 (en) 2009-02-19
AU2007217779A1 (en) 2007-08-30
CA2638803A1 (en) 2007-08-30
EP1984395A2 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
AR060104A1 (es) Modulacion de la formacion de huesos
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
GT201200271A (es) Proteínas que se unen al tnf-a
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3
DE602004030354D1 (de) Systeme mit wechselbaren hörnern zur herstellung von eingeschlossenen produkten
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
CY1114887T1 (el) Συνθεσεις και μεθοδοι παρασκευης συνθεσης
CO6382161A2 (es) Moleculas biespecificas de union a egfr/igfir
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
BR112012026766A2 (pt) métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica.
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
CR9294A (es) Formulaciones de polipeptido liquidas estabilizadas
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal